AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca seloken / Toprol-XL (metoprolol) — Established RoW YoY actual (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
12.0%
Period ended Jun 30, 2026
Change on a year earlier
+17.0 pts
-5.0% in Q2 2025
History
22 quarters
Since Q4 2020
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Seloken / Toprol-XL (metoprolol) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 12.0% | +17.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -12.0% | 0.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 48.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 3.0% | +61.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -5.0% | +35.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -12.0% | +27.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | -58.0% | -54.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | -40.0% | -12.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -39.0% | -16.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | -34.0% | -11.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | -4.0% | +14.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | -28.0% | -15.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -23.0% | -16.0 pts | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -23.0% | -37.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | -18.0% | -33.0 pts | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | -13.0% | -38.0 pts | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q1 2022 | Mar 31, 2022 | -7.0% | +6.0 pts | Form 6-K FY2022Q1 Earnings Release ↗ |
| Q4 2021 | Dec 31, 2021 | 14.0% | +21.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| Q3 2021 | Sep 30, 2021 | 15.0% | – | Form 6-K FY2021Q3 Earnings Release ↗ |
| Q2 2021 | Jun 30, 2021 | 25.0% | – | Form 6-K FY2021Q2 Earnings Release ↗ |
| Q1 2021 | Mar 31, 2021 | -13.0% | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | -7.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Seloken / Toprol-XL (metoprolol) — Established RoW YoY actual (%) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_seloken_erow_act_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.